Camylofin 50 mg and Paracetamol 325 mg in patients with acute colicky abdominal pain: a prospective and open-label study

Chandravati

doi:10.18203/2320-1770.ijrcog20243934

Authors

Chandravati Krishna Medical Centre, I-Rana Pratap Marg, Hazratganj, Lucknow, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20243934

Keywords:

Abdominal colic, Camylofin, Paracetamol

Abstract

Background: Acute colicky abdominal pain (AP), resulting from the sudden spasm of hollow viscera, is frequently managed with a combination of analgesics and antispasmodics. Camylofin is an anti-spasmodic medication whereas paracetamol is a widely prescribed analgesic and antipyretic for managing mild-to-moderate pain. This study evaluates the effectiveness of a fixed-dose combination (FDC) of camylofin 50 mg and Paracetamol 325 mg in alleviating acute colicky abdominal pain.

Methods: In this prospective, single-arm, open-label study, 100 female patients aged 18-65 with acute colicky abdominal pain were administered one tablet thrice daily for 3-5 days of camylofin 50 mg and paracetamol 325 mg daily for 3-5 days. Pain intensity was assessed using the visual analog scale (VAS) at baseline, Day 3 and Day 5.

Results: A significant reduction was observed in the mean VAS scores from baseline (77.8) to Day 5 (4.0) (p<0.001). At day 5, 83.0% of patients reported no pain, with minimal adverse events (2% fever and 1% headache with fever). There was a significant change (-27.5) in mean pain intensity VAS score before (77.8) and after (50.2) medication, p<0.001. The percentage change in the mean pain intensity based on VAS score was highest in subjects with urinary AP (97.4%), followed by menstrual AP (94.9%) and unexplained AP (94.5%).

Conclusions: The FDC of camylofin 50 mg and Paracetamol 325 mg is significantly effective in managing acute colicky abdominal pain, providing rapid and substantial pain relief with minimal adverse events.

Metrics

Metrics Loading ...

References

Gray J, Wardrope J, Fothergill DJ. 7 Abdominal pain, abdominal pain in women, complications of pregnancy and labour. Emerg Med J. 2004;21(5):606-13.

Cartwright SL, Knudson MP. Evaluation of Acute Abdominal Pain in Adults. Am Fam Physician. 2008;77(7):971-8.

Mayadeo N. Role of camylofin and its combinations in obstetrics and gynaecological practice: a review of Indian evidence. Int J Reprod Contracept Obstet Gynecol. 2019;8:343-8.

Brenner DM, Lacy BE. Antispasmodics for chronic abdominal pain: analysis of North American treatment options. Am J Gastroenterol. 2021;116(8):1587-600.

Abdullah M, Firmansyah MA. Diagnostic approach and management of acute abdominal pain. Acta Med Indones. 2012;44(4):344-50.

Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675-88.

Zheng L, Lai Y, Lu W, Li B, Fan H, Yan Z, et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial. Clin Gastroenterol Hepatol 2015;13:1285–92.

Bahreini M, Jalili M, Moradi-Lakeh M. A comparison of three self-report pain scales in adults with acute pain. J Emerg Med. 2015;48:10-8.

Karcioglu O, Topacoglu H, Dikme O, Dikme O. A systematic review of the pain scales in adults: Which to use? Am J Emerg Med. 2018;36:707-14.

Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain. Arthritis Care Res. 2011;63(S11):240-52.

Dhandapani S, Das S, Gangadhar A. A randomised, comparative study to evaluate the efficacy and tolerability of two fixed dose combinations of camylofin and mefenamic acid and dicyclomine and mefenamic acid in the management of primary dysmenorrhea. Ind Practitioner. 2017;70:16-20.

Pandey P. Assessing the impact of a fixed dose combination of camylofin and mefenamic acid on the onset of pain relief in patients with moderate to severe dysmenorrhea. Int J Reprod Contracept Obstet Gynecol. 2022;11:2991-6.

Warke HS, Chauhan AR, Raut VS, Ingle KM. A randomised double-blind trial-Bombay Hospital Journal. J Clin Diagn Res. 2013;7(9):1897-9.

Mayadeo N. Camylofin dihydrochloride injection: a drug monograph review. Int J Reprod Contracept Obstet Gynecol. 2019;8:360-68.

de los Santos AR, Zmijanovich R, Pérez Macri S, Martí ML, DiGirolamo G. Antispasmodic/ analgesic associations in primary dysmenorrhea double-blind crossover placebo-controlled clinical trial. Int J Clin Pharmacol Res. 2001;1:21-9.

Mueller-Lissner S, Tytgat GN, Paulo LG, Quigley EMM, Bubeck J, Peil H, et al. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther. 2006;23:1741-8.

Nagendra K., Sarvanan P., Pandey DC, Bhosale MN, Jindal K, Hanse U. A prospective, single-arm, open-label, multicenter study to determine the safety and effectiveness of a fixed dose combination of camylofin dihydrochloride and paracetamol in Indian children with acute colicky abdominal pain. Int J Contemp Pediatr 2022;9:706- 12.

Janczura M, Kobus-Moryson M, Sip S, Żarowski M, Wareńczak A, Cielecka-Piontek J. Fixed-dose combination of NSAIDs and spasmolytic agents in the treatment of different types of pain-a practical review. J Clin Med. 2021;10(14):3118.